PHARMACOKINETICS OF ONCE-DAILY SOFOSBUVIR OR LEDIPASVIR/SOFOSBUVIR IN HCV-INFECTED PEDIATRICS AGED 3 TO

被引：0
|
作者：
Begley, Rebecca [1 ]
Meng, Amy [1 ]
Massetto, Benedetta [1 ]
Shao, Jiang [1 ]
Yip, Christina Sze Man [1 ]
Ling, John [1 ]
Mathias, Anita [1 ]
机构：
[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
GUT | 2019年 / 68卷
关键词：
D O I：
10.1136/gutjnl-2019-IDDFabstracts.269
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
IDDF2019-A
引用
收藏
页码：A137 / A138
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics of Once Daily Sofosbuvir or Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 3 to <6 Years Old
    Begley, Rebecca
    Meng, Amy
    Massetto, Benedetta
    Shao, Jiang
    Ling, John
    Mathias, Anita
    HEPATOLOGY, 2018, 68 : 582A - 582A
  • [2] Pharmacokinetics of Once Daily Sofosbuvir or Ledipasvir/Sofosbuvir in HCV-Infected Adolescents
    Kirby, Brian
    German, Polina
    Kanwar, Bittoo
    Ni, Liyun
    Lakatos, Isobel
    Ling, John
    Mathias, Anita
    HEPATOLOGY, 2015, 62 : 1040A - 1041A
  • [3] Pharmacokinetics of Once Daily Sofosbuvir or Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 6 to <12 Years Old
    Garrison, Kimberly L.
    Mathias, Anita
    Kersey, Kathryn
    Kanwar, Bittoo
    Ni, Liyun
    Jain, Anant
    Ling, John
    Gonzalez-Peralta, Regino P.
    Murray, Karen F.
    Lin, C-H
    Whitworth, Mary Suzanne
    Wen, Jessica
    Schwarz, Kathleen B.
    Balistreri, William
    HEPATOLOGY, 2016, 64 : 436A - 436A
  • [4] SAFETY AND EFFICACY OF TREATMENT WITH ONCE-DAILY LEDIPASVIR/SOFOSBUVIR (90/400 MG) FOR 12 WEEKS IN GENOTYPE 1 HCV-INFECTED PATIENTS WITH SEVERE RENAL IMPAIRMENT
    Lawitz, Eric
    Landis, Charles S.
    Maliakkal, Benedict J.
    Bonacini, Maurizio
    Ortiz-Lasanta, Grisell
    Zhang, Jie
    Mogalian, Erik
    De-Oertel, Shampa
    Osinusi, Anu O.
    Brainard, Diana M.
    McHutchison, John G.
    Yip, Christina Sze Man
    Huang, Hai Cheng
    Flamm, Steven L.
    Gordon, Stuart C.
    Gane, Edward J.
    GUT, 2018, 67 : A99 - A100
  • [5] Safety and Efficacy of Treatment with Once-Daily Ledipasvir/Sofosbuvir (90/400 mg) for 12 Weeks in Genotype 1 HCV-Infected Patients with Severe Renal Impairment
    Lawitz, Eric
    Landis, Charles S.
    Maliakkal, Benedict J.
    Bonacini, Maurizio
    Ortiz-Lasanta, Grisell
    Zhang, Jie
    Mogalian, Erik
    De-Oertel, Shampa
    Osinusi, Anu O.
    Brainard, Diana M.
    McHutchison, John G.
    Flamm, Steven L.
    Gordon, Stuart C.
    Gane, Edward J.
    HEPATOLOGY, 2017, 66 : 848A - 848A
  • [6] Sofosbuvir and ledipasvir for HIV/HCV co-infected patients
    Rosenthal, Elana S.
    Kottilil, Shyam
    Polis, Michael A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (05) : 743 - 749
  • [7] PHARMACOKINETIC ANALYSES OF LEDIPASVIR/SOFOSBUVIR IN HCV-INFECTED SUBJECTS WITH ADVANCED LIVER DISEASE AND/OR FOLLOWING LIVER TRANSPLANTATION
    Garrison, K. L.
    German, P.
    Arterburn, S.
    De-Oertel, S.
    Brainard, D.
    Ling, J.
    Jin, F.
    Mathias, A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S789 - S789
  • [8] Decline in eGFR in HCV-infected patients while on treatment with sofosbuvir/ledipasvir or PrOD regimens is not dependent on baseline eGFR
    Alkadi, M.
    Ren, Y.
    Abou-Samra, A-B
    Puenpatom, A.
    Arduino, J. M.
    Kumar, R.
    Butt, A. A.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S724 - S724
  • [9] Safety and Efficacy of Ledipasvir/Sofosbuvir without on-Treatment Laboratory Monitoring in HCV-Infected Rwandans: The Shared 2 Study
    Grant, Philip
    Kabahizi, Jules
    Mbituyumuremyi, Aimable
    Van Nuil, Jennifer Ilo
    Mukabatsinda, Constance
    Damascene, Makuza Jean
    Shumbusho, Fabienne
    Ntirenganya, Cyprien
    Nsanzimana, Sabin
    Gupta, Neil
    HEPATOLOGY, 2018, 68 : 36A - 36A
  • [10] Hepatotoxicity and potential drug interaction with ledipasvir/sofosbuvir in HIV/HCV infected patients
    Tseng, Alice
    Wong, David K.
    JOURNAL OF HEPATOLOGY, 2016, 65 (03) : 651 - 653
12345